NextBioForm has been granted prolongation from Vinnova!
The centre now has funding until 2023. We are very thankful for this opportunity and look forward the coming productive years!
The first publication from NextBioForm is entitled ‘Proteins and antibodies in serum, plasma, and whole blood—size characterization using asymmetrical flow field-flow fractionation (AF4)’ and describes the first analyses of proteins in serum and blood using AF4-techniques.
PepTalk: The Protein Science Week 14-18 January 2019
NextBioForm contributed with two invited talks presented by Anna Fureby and Ulla Elofsson at The Protein Science Week, one of the largest annual gatherings of protein science researchers in the world, and covers protein engineering, processing, formulation and analytics. The international delegation of over 1,300 participants convene for intensive learning and networking to discover new opportunities, apply alternative solutions, and develop promising partnerships.
Therapeutical proteins – focus on analysis and formulations, 5-6 February 2019
The Swedish Academy of Pharmaceutical Sciences is organising a minisymposium to review the state of the art of analytical tools and formulation concepts as applied to therapeutic proteins, and to highlight the needs of new innovative solutions for remaining problems. More information
Beam time 3-4 September 2018
Joint workshop NextBioForm and Swedish Drug Delivery Forum 27-28 June 2018
NextBioForm organised a successful first joint workshop for NextBioForm and SDDF (coordinated by Uppsala University) in Lund on June 27-28 2018. Many thanks to the local organisers at LTH and MAX IV for the excellent arrangements! This was a good opportunity learn more about both centres and the research projects, both centres work on different aspects of drug formulation and drug delivery. Several interesting talks were held and nice posters were shown. The purpose of the joint workshop was to get acquainted and share information on our activities, and included in the program was a tour to MAXIV.